Xenon Pharmaceuticals, Inc. (XENE)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Xenon Pharmaceuticals, Inc. (XENE)
Company Performance

Current Price

as of Oct 16, 2024

$42.62

P/E Ratio

N/A

Market Cap

$3.23B

Description

Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Metrics

Overview

  • HQBurnaby, BC
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerXENE
  • Price$42.62+4.69%

Trading Information

  • Market Cap$3.23B
  • Float97.44%
  • Average Daily Volume (1m)313,185
  • Average Daily Volume (3m)343,142
  • EPS-$2.74

Company

  • RevenueN/A
  • Rev Growth (1yr)N/A
  • Net Income-$57.92M
  • Gross MarginN/A
  • EBITDA MarginN/A
  • EBITDA-$68.45M
  • EV$2.32B
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/B3.82
Documents
SEC Filings
8-K (2024-08-08)
8-K (2024-06-05)
8-K (2024-05-09)
8-K (2024-04-19)
8-K (2024-03-08)
8-K (2024-02-29)
8-K (2023-11-30)
8-K (2023-11-27)
8-K (2023-11-09)
8-K (2023-11-08)
8-K (2023-08-09)
8-K (2023-08-08)
8-K (2023-06-02)
8-K (2023-05-09)
8-K (2023-03-14)
8-K (2023-03-08)
8-K (2023-03-01)
10-Q (2024-08-08)
10-Q (2024-05-09)
10-Q (2023-11-08)
10-Q (2023-08-09)
10-Q (2023-05-09)
10-K (2024-02-29)
10-K (2023-03-01)
Earnings Calls
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report 2023Q4
Earnings Report (2023-11-08)
Earnings Report (2023-08-09)
Factset Street Account
Xenon Pharmaceuticals reports topline results from phase 2 proof-of-concept X-NOVA trial of XEN1101 in major depressive disorder; call at 8:30ET ($28.97, 0.00) (2023-11-27T12:03:37Z)
Xenon Pharmaceuticals reports Q3 EPS ($0.73) vs FactSet ($0.77) [15 est, ($0.89)-(0.54)] ($31.91, 0.00) (2023-11-08T21:03:03Z)
Xenon Pharmaceuticals reports pricing of upsized $300.0M offering through J.P. Morgan, Jefferies, BofA Securities, Stifel, and RBC Capital Markets ($33.75, 0.00) (2023-11-30T03:56:56Z)
Xenon Pharmaceuticals provides updates on neurology pipeline programs at AES 2023 ($36.80, 0.00) (2023-12-02T21:03:41Z)
Xenon Pharmaceuticals announces publication of results from XEN1101 phase 2b "X-TOLE" clinical trial ($35.49, 0.00) (2023-10-09T20:17:25Z)
Xenon Pharmaceuticals announces proposed $225M public common stock offering including pre-funded warrants through J.P. Morgan, Jefferies, BofA Securities, Stifel, and RBC Capital Markets ($33.94, 0.00) (2023-11-29T21:06:25Z)